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Abstract
Purpose:	A	retrospective,	cohort	study	was	conducted	between	2009	and	2017	in	a	
private	infertility	center	to	determine	the	predictive	value	of	endogenous	estrogen	
(E2)	and	progesterone	 (P4)	 levels	 in	hormone‐replacement	frozen	embryo	replace‐
ment (FER) treatment cycles.
Methods:	A	total	of	120	consecutive,	infertile	patients	who	became	pregnant	after	
FER	cycles	were	analyzed	(age:	37.4	±	4.4	years).	Electively	vitrified	blastocysts	were	
created	during	natural	cycle	IVF	or	mild	ovarian	stimulation	treatments	and	subse‐
quently	transferred	through	delayed	vitrified‐thawed	blastocyst	transfer	cycles	sup‐
plemented	with	estrogens	and	a	combination	of	synthetic	progestogens.	Serum	E2	
and	progesterone	P4	levels	were	intensively	monitored	every	five	days	(from	the	day	
after	embryo	transfer	until	9w1d	of	pregnancy)	and	compared	among	patients	with	a	
subsequent	live	birth	(n	=	76)	or	first‐trimester	pregnancy	loss	(n	=	44).
Results:	Endogenous	placental	activity	started	as	early	as	5‐6th	pregnancy	week	dif‐
fering	 significantly	 according	 to	 pregnancy	 outcome.	 For	 P4,	 the	 exponential	 rise	
from	6w2d	onwards	allowed	distinguishing	between	failing	and	successful	concep‐
tions.	 For	P4,	 lower	 quartiles	 of	 the	 live	 birth	 group	did	 not	 intersect	with	 upper	
quartiles	of	the	miscarriage	group.
Conclusions:	 Innovative	FER	protocols	 incorporating	synthetic	progestogens	allow	
the	correct	measurement	of	endogenous	placental	activity	and	could	help	to	monitor	
early	first‐trimester	ART	pregnancies.
K E Y W O R D S
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1  | INTRODUC TION
Frozen	embryo	replacement	(FER)	cycles	are	on	the	increase	world‐
wide	 due	 to	 the	 introduction	 of	 more	 efficient	 cryopreservation	
methods,	the	push	toward	an	elective	single	embryo	transfer	(SET)	
policy,	 as	well	 as	 the	 spread	 of	 segmented	 IVF	 cycles	 in	 cases	 of	
premature	progesterone	elevation,	preimplantation	genetic	testing	
(PGT),	 or	 the	 recently	 advocated	 “freeze‐all”	 strategy1.	 In	 Japan,	
these	trends	are	particularly	strong,	and	according	to	a	national	IVF	
registry,	 in	 2015,	 frozen‐thawed	 cycles	 constituted	 approximately	
70%	of	 fresh	 treatments,	whereas	 single	embryo	 transfer	was	 the	
highest in the world at 80%2.
Parallel	to	these	developments,	endometrial	preparation	protocols	
have	evolved	little	since	their	first	description3.	To	date,	according	to	
several	systematic	 reviews,	no	endometrial	preparation	regime	or	a	
combination	of	specific	drugs	has	proved	itself	superior	compared	to	
any	 other	 protocol.4,5	 Supplemented	 estrogen/progesterone‐based	
protocols	 are	 convenient	 because	 they	 require	minimal	monitoring	
and	could	be	easily	scheduled.	However,	compared	to	natural	cycles,	
they	are	associated	with	an	increased	medication	cost,	potential	side	
effects,	 and	 inconveniences	of	 vaginal	or	 intramuscular	 administra‐
tion.1	Therefore,	less‐investigated	synthetic	progestogens	(especially	
dydrogesterone)	could	become	a	very	useful	alternative	to	the	more	
widely	used	natural	progesterone	preparations,	and	they	could	also	
allow	the	precise	monitoring	of	endogenous	placental	activity.
Thus,	 the	aim	of	this	retrospective	review	was	to	examine	pla‐
cental	 steroid	 output	 in	 FER	 cycles	 supplemented	with	 estrogens	
and	 a	 unique	 combination	 of	 synthetic	 progestogens	 in	 a	 cohort	
of	 intensively	 monitored	 pregnant	 patients.	 This	 design	 has	 also	
enabled	us	 to	precisely	 time	 the	onset	of	 the	 luteo‐placental	 shift	
during	an	early	first‐trimester	pregnancy.
2  | MATERIAL S AND METHODS
2.1 | Study patients
This	retrospective	review	included	all	consecutive	patients	(n	=	126)	
from	a	single	center	(Kobe	Motomachi	Yume	Clinic,	Kobe,	Japan)	be‐
tween	 June	2009	and	April	2017	who	became	pregnant	after	 sin‐
gle	vitrified‐warmed	blastocyst	transfer	(SVBT)	cycles	and	satisfied	
the	following	 inclusion	criteria:	 (a)	underwent	artificial	endometrial	
preparation	with	oral	estrogens	and	a	combination	of	synthetic pro-
gestogens only	(patients	with	other	protocols	were	not	included),	(b)	
completed	 intensive	 hormonal	 monitoring	 with	 measurements	 of	
their	endogenous	serum	estrogen	(E2)	and	progesterone	(P4)	levels	
every	 five	days	 (from	 the	day	after	embryo	 transfer	until	9w1d	of	
pregnancy),	(c)	the	first	ultrasound	examination	showed	the	presence	
of	at	 least	one	gestational	sac	(thus,	biochemical	pregnancies	were	
not	 included),	 and	 (d)	pregnancy	outcome	was	known	 to	be	either	
live	birth	 (n	=	76)	or	a	 first‐trimester	miscarriage	 (n	=	44).	Exclusion	
criteria	were	as	follows:	monozygotic	twinning	(n	=	5)	or	a	voluntary	
termination	of	pregnancy	(n	=	1).	This	retrospective	was	based	on	an‐
onymized,	retrospective	review	of	data	and	involved	established	clin‐
ical	procedures	performed	routinely	 in	our	center,	and	 its	research	
protocol	was	approved	by	a	local	Institutional	Review	Board.6
2.2 | Patient screening, ovarian stimulation, and 
laboratory procedures
Before	 treatment	 starts,	 all	 women	 had	 a	 normal	 basic	 fertility	
workup,	 including	 hysterosonography,	 hysterosalpingography,	 or	
laparoscopy	 in	 most	 of	 them.	 Unstimulated	 natural	 cycle	 IVF	 or	
clomiphene	citrate‐based	minimal	stimulation	was	used	as	a	main‐
stream	 treatment	 in	 our	 clinic.	 Details	 of	 these	 protocols	 were	
described	previously.7,8	Fertilized	zygotes	were	cultured	until	blasto‐
cyst	stage	and	vitrified	electively.9	Since	the	inception	of	our	center,	
only	single	embryo	transfers	(SET)	were	performed	and	a	universal	
SET	policy	was	strictly	observed.	These	delayed	FERs	were	usually	
performed	within	the	3‐month	period	following	the	oocyte	retrieval	
from	where	embryos	originated.
2.3 | Endometrial preparation protocol and 
luteal support
Details	of	endometrial	preparation	and	luteal	support	in	FER	pro‐
tocols	are	summarized	in	Figure	1.	In	cycling	patients,	oral	estro‐
gen	tablets	4‐6	mg/d	(Julina,	Bayer,	Japan)	were	started	from	the	
onset	(day	2‐3)	of	a	spontaneous	menstrual	bleeding	and	continued	
throughout	 the	 endometrial	 preparation.	 Endometrial	 thickness	
was	checked	by	transvaginal	ultrasound	at	day	10,	and	if	reaching	
at	 least	7	mm,	oral	dydrogesterone	 tablets	30	mg/d	 (Duphaston,	
Mylan	EPD,	Japan)	were	started	from	day	11.	Four	days	afterward	
(day	14),	oral,	combined	contraceptive	tablets	(containing	0.05	mg	
ethinylestradiol,	 0.5	mg	 norgestrel)	 were	 also	 added	 (Planovar;	
Aska	Pharmaceutical	Co.,	Tokyo,	Japan)	in	order	to	block	the	de‐
velopment	of	any	dominant	 follicle	and	prevent	spontaneous	LH	
surges.	Vitrified‐thawed,	single	blastocyst	transfer	was	scheduled	
four	days	later	(day	18),	and	the	above	drugs	were	continued	until	
the	pregnancy	test	day.	To	avoid	any	effect	on	endogenous	pro‐
gesterone	 levels,	 patients	 in	 this	 study	have	not	used	 any	 luteal	
support	containing	natural	progesterone	preparations.	β‐hCG	lev‐
els	were	 tested	 three	 times;	 at	 first	 five	 days	 following	 embryo	
transfer	and	twice	afterward	(4w1d	and	4w6d)	to	confirm	steadily	F I G U R E  1  Endometrial	preparation	protocol	and	follow‐up
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rising	 levels	 and	 to	exclude	biochemical	pregnancies.	Patients	 in	
this study have undergone intensive hormonal monitoring with 
measurement	of	their	endogenous	serum	E2	and	P4	levels	every	
five	days	(from	the	day	after	embryo	transfer	until	9w1d).	A	first	
transvaginal	ultrasound	examination	was	performed	at	around	4‐5	
pregnancy	 weeks.	 Patients	 with	 an	 ultrasound‐confirmed	 ongo‐
ing	pregnancy	 reaching	at	 least	nine	pregnancy	weeks	were	dis‐
charged	to	their	treating	gynecologists	for	further	obstetrical	care	
and	were	only	contacted	later	when	ascertaining	the	final	repro‐
ductive outcome.
2.4 | Hormonal assays
Sera	were	analyzed	for	E2	and	P4	at	the	clinic	immediately	after	blood	
drawing	using	the	iE2	and	PROGIII	enzyme	immunoassay	kit	accord‐
ing	to	the	manufacturer’s	instructions	(Tosoh	Corp.,	Tokyo,	Japan).	The	
synthetic	progestogens	used	(dydrogesterone	and	norgestrel)	did	not	
have	any	cross‐reaction	with	the	progesterone	assay.
2.5 | Outcome measures and statistical analysis
Early,	first‐trimester	miscarriage	was	defined	as	pregnancy	loss	occur‐
ring	after	detection	of	 a	gestational	 sac	 following	an	 initial	 scanning	
at	4‐5	weeks.	Live	birth	was	defined	as	a	child	born	after	22	weeks	or	
weighing	at	least	500	g.	Hormonal	levels	of	the	live	birth	and	miscarriage	
groups	were	compared	using	the	Mann‐Whitney	U	test	due	to	non‐nor‐
mal distribution. P	<	0.05	was	considered	statistically	significant.
3  | RESULTS
3.1 | Reproductive outcome and patient age
Out	of	a	 total	120	pregnant	patients	with	a	confirmed	gestational	
sac,	44	(36%)	suffered	a	first‐trimester	pregnancy	loss	and	76	(64%)	
achieved	a	singleton	live	birth.	Patients	with	a	pregnancy	loss	were	
significantly	older	compared	to	 their	counterparts	who	achieved	a	
live	birth	(40.2	±	3.2	vs	35.8	±	4.3	years,	P < 0.0001). The endome‐
trial	thickness	measured	during	the	first	phase	of	estrogen	supple‐
mentation	was	slightly	thinner	in	the	pregnancy	loss	group	(9.7	±	1.9	
vs	10.4	±	1.8	mm,	P	=	0.036).
3.2 | Serum hormonal levels during the 
first trimester
In	both	groups,	serum	hormonal	 levels	were	steady	until	4w1d	for	
E2	and	5w4d	for	P4.	For	P4,	they	were	uniformly	very	low	(<1	ng/
mL)	 indicating	 the	 absence	 of	 any	 endogenous	 placental	 activity,	
whereas	 for	 E2,	 physiological	 levels	 were	 observed	 (200‐300	pg/
mL)	 as	 expected	 following	 oral	 estrogen	 supplementation.	 From	
4w6d	onwards	for	E2	and	somewhat	later	at	6w2d	for	P4,	there	was	
an	increase	for	both	steroid	hormones	heralding	the	onset	of	placen‐
tal	secretion.	This	 increase	was	exponential	 in	 the	 live	birth	group	
and	much	more	pronounced	for	P4	than	E2.	On	the	other	hand,	in	
the	miscarriage	group,	E2	started	to	plateau	and	P4	has	risen	only	
weakly.	For	P4,	from	6w2d	onwards,	the	lower	quartiles	(bottom	of	
the	box)	of	the	live	birth	group	did	not	intersect	with	the	upper	quar‐
tiles	(top	of	the	box)	of	the	miscarriage	group.	For	E2,	however,	such	
distinction	was	only	observed	toward	the	end	of	the	follow‐up	pe‐
riod	after	8w3d.	Serum	E2	and	P4	levels	until	9w1d	are	summarized	
in	Tables	1‐2	and	depicted	as	box	plots	in	Figures	2‐3.
4  | DISCUSSION
Our	retrospective	cohort	study	suggests	that	in	frozen	embryo	re‐
placement	cycles	substituted	with	estrogens	and	a	combination	of	
synthetic	 progestogens,	 the	 rising	 endogenous	 progesterone	 lev‐
els	could	be	used	to	predict	the	outcome	of	an	early	first‐trimester	
TA B L E  1  Quartiles	of	serum	E2	hormonal	levels	(pg/ml)	according	to	pregnancy	outcome,	Q1:	first	quartile,	Q3:	third	quartile
2w5d 3w3d 4w1d 4w6d 5w4d 6w2d 7w0d 7w5d 8w3d 9w1d
Live	birth
Max 411 332 374 537 826 1103 1888 2049 2500 2563
Q3 266 233 250 339 467 703 873 1140 1248 1390
Median 213 192 201 302 386 543 680 886 1029 1104
Q1 174 150 170 260 329 426 534 706 796 877
Min 119 107 112 132 210 263 339 356 548 538
Miscarriage
Max 382 400 314 437 549 750 895 1085 1167 918
Q3 288 236 255 320 392 470 641 725 703 854
Median 218 204 215 286 352 396 485 559 566 584
Q1 185 165 176 248 298 334 421 437 478 494
Min 121 111 82 194 207 21 167 9 421 46
P NS NS NS NS ** *** *** *** *** ***
Mann‐Whitney	U	test,	NS	>0.05,	*<0.05,	**<0.01,	***<0.001,	****<0.0001.
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pregnancy.	Moreover,	this	unique	endometrial	preparation	protocol	
also	provides	evidence	of	an	endogenous	(luteo)‐placental	shift	oc‐
curring	as	early	as	from	the	5‐6th	pregnancy	week.
The	 unique	 treatment	 approaches	 used	 in	 our	 study	were	 de‐
rived	from	decades	of	experience	in	a	Japanese	center	that	has	rou‐
tinely	used	the	above	innovative	protocols	including	minimal	ovarian	
stimulation,	 elective	 embryo	 vitrification,	 and	 delayed	 vitrified‐
thawed	blastocyst	transfers.8	In	fact,	our	group	(Kato	Ladies	Clinic,	
Tokyo	and	its	branches)	has	already	employed	these	approaches	on	
a	 large‐scale	basis,	before	embryo	vitrification	and	the	“freeze‐all”	
strategy	was	increasingly	advocated	in	the	Western	reproductive	lit‐
erature.10	In	the	same	manner,	our	endometrial	preparation	protocol	
is	 also	 quite	 unique	 in	 that	 it	 includes	 a	 combination	 of	 synthetic	
progestogens	instead	of	the	elsewhere	more	widely	used	(vaginally	
or	intramuscularly	administered)	natural	progesterone	preparations.
So	far,	according	to	numerous	reviews,	no	endometrial	prepa‐
ration	 regime	 (natural	 or	 supplemented	 cycle)	 or	 a	 combination	
of	 specific	 drugs	 has	 proved	 itself	 superior	 compared	 to	 other	
alternative	 FER	 protocols.4,5	 In	 our	 study,	 we	 have	 used	 dydro‐
gesterone	 which	 is	 an	 orally	 administered	 synthetic	 progesto‐
gen	 that	 has	 been	 successfully	 used	 for	 luteal‐phase	 support	 in	
stimulated	 IVF	 cycles	 for	 many	 decades.11‐16 Due to its unique 
molecular	 structure,	 it	 has	 a	more	 selective	 binding	 capacity	 to	
the	natural	 progesterone	 receptor;	 therefore,	much	 lower	doses	
are	required	compared	to	micronized	progesterone.17	 It	 is	cheap,	
has	 an	 excellent	 safety	 profile,	 and	 is	 associated	with	 increased	
patient	satisfaction	due	to	the	 lack	of	the	side	effects	of	vaginal	
(irritation,	discharge,	bleeding,	interference	with	sexual	life)	or	in‐
tramuscular	 administration	 (local	 inflammation,	 abscesses,	 pain,	
anaphylactic	 reaction).	 In	 a	 recent	 systematic	 review	 and	meta‐
analysis	involving	eight	randomized	clinical	trials,	dydrogesterone	
was	 found	 to	be	 as	 effective	 as	 vaginal	 progesterone	 for	 luteal‐
phase	support	in	stimulated	IVF	cycles.	This	was	also	corroborated	
by	a	more	recent,	large,	multicentric	phase	III	trial	involving	1301	
randomized	 subjects	 confirming	 the	 noninferiority	 of	 dydroges‐
terone	 (30	mg/d)	 to	micronized	vaginal	progesterone	 (600	mg/d)	
in	the	setting	of	conventional	IVF	treatment	cycles.18	However,	up	
to	day,	there	are	no	similar	studies	involving	dydrogesterone	in	the	
setting	of	FER	cycles.
Apart	from	the	use	of	synthetic	progestogens,	our	endometrial	
preparation	 protocol	 also	 has	 other	 distinctive	 features	 setting	
it	 apart	 from	 various	 other	 HRT‐based	 supplemented	 protocols	
described	in	the	literature.	When	sufficient	endometrial	develop‐
ment	has	been	detected	by	ultrasound	scanning	after	10	days	of	
TA B L E  2  Quartiles	of	serum	P4	hormonal	levels	(ng/ml)	according	to	pregnancy	outcome,	Q1:	first	quartile,	Q3:	third	quartile
2w5d 3w3d 4w1d 4w6d 5w4d 6w2d 7w0d 7w5d 8w3d 9w1d
Live	birth
Max 2.7 2.3 2.4 2.2 2.0 5.2 14.7 24.2 24.4 29.3
Q3 0.7 0.6 0.67 0.6 1.0 2.2 5.2 9.8 13.4 18.6
Median 0.6 0.5 0.5 0.6 0.8 1.72 3.7 7.4 10.9 13.9
Q1 0.45 0.4 0.45 0.40 0.6 1.2 2.5 4.7 7.2 10.0
Min 0.2 0.3 0.3 0.3 0.4 0.6 1.10 1.9 3.4 6.7
Miscarriage
Max 2.5 1.2 1.4 1.3 1.4 2.5 5.5 8.7 12.5 15.9
Q3 0.6 0.6 0.5 0.6 0.7 1.2 2.3 3.7 7.9 6.9
Median 0.5 0.5 0.5 0.5 0.6 0.8 1.4 2.4 4.4 5.8
Q1 0.4 0.4 0.4 0.4 0.4 0.6 0.9 1.6 2.9 3.8
Min 0.3 0.2 0.3 0.2 0.2 0.2 0.3 0.2 1.3 1.7
P NS NS * NS *** *** *** *** *** ***
Mann‐Whitney	U	test,	NS	>0.05,	*<0.05,	**<0.01,	***<0.001,	****<0.0001.
F I G U R E  2  E2	hormonal	levels	(pg/ml)	according	to	pregnancy	
outcome	(LB:	live	birth;	Misc:	miscarriage)
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a	 full	 dose	 of	 oral	 estrogen	 administration,	 dydrogesterone	was	
started	from	day	11	onwards.	This	 is	 to	mimic	 the	slight	proges‐
terone	rise	 (1‐3	ng/mL)	which	occurs	 in	a	natural	cycle	 (12	hours	
to	3	days	prior	 to	ovulation)	 and	 is	 not	 thought	 to	 influence	 the	
window	of	 implantation.	Following	this	 from	day	14	onwards,	an	
oral	contraceptive	pill	was	also	added	 (also	containing	additional	
synthetic	progestogen)	and	day‐5	blastocyst	transfer	was	sched‐
uled	four	days	later	on	day	18.	This	is	in	line	with	the	established	
recommendation	of	transferring	blastocysts	after	4	to	5	full	days	
of	 natural	 progesterone	 supplementation.1 Although the addi‐
tion	 of	 a	 contraceptive	 pill	 might	 seem	 unorthodox,	 it	 could	 be	
also	 beneficial	 by	 avoiding	 escape	 ovulations	which	 are	 thought	
to	 occur	 in	 1.9%‐7.4%	 of	 supplemented	 cycles	without	 pituitary	
suppression.	Contraceptive	pill	cotreatment	was	used	in	our	clinic	
group’s	 FER	protocol	 for	 decades	without	 observing	 any	 signifi‐
cant	adverse	effects.19,20
Our	study	findings	are	comparable	with	a	small	US	series	from	
the	1990s,	 in	which	the	onset	of	placental	steroid	production	was	
studied	in	nine	oocyte	recipient	patients.21	Although—unlike	in	our	
study—those	patients	were	 substituted	with	a	 conventional	estro‐
gen‐progesterone	protocol,	the	authors	have	still	managed	to	detect	
a	significant	 increase	 in	secreted	steroid	 levels	beginning	from	the	
6‐7th	pregnancy	week	onwards	and	estimated	the	onset	of	placen‐
tal	 secretion	 at	 the	 5th	 pregnancy	week.	 This	 was	 approximately	
3	weeks	earlier	than	thought	previously,	based	on	early	experimen‐
tal	 studies	of	 luteo‐placental	 shift	 in	humans.22,23	 In	our	 study,	an	
unequivocal	endogenous	progesterone	increase	has	appeared	from	
the	6w2d	onwards	and	continued	exponentially	in	case	of	a	success‐
ful	ongoing	pregnancy.
As	for	potential	endocrine	markers	that	could	predict	early	preg‐
nancy	failure,	progesterone	currently	seems	to	be	the	most	promising	
one.24	A	recent	large	prospective	cohort	study	from	Singapore	iden‐
tified	 a	 level	of	<11	ng/mL	 (35	nmol/L)	 that	 could	 identify	women	
during	their	first	trimester	(4‐12	weeks)	who	are	later	likely	to	suffer	
a	spontaneous	miscarriage.25	Although	this	threshold	is	comparable	
with	median	P4	 levels	 in	our	 live	birth	group	 (around	10	ng/mL	at	
8‐9	weeks),	 it	must	be	emphasized	that	our	P4	levels	should	be	in‐
herently	lower	because	of	the	absence	of	any	internal	corpus	luteum	
production.	The	clinical	utility	of	a	specific	threshold	valid	for	syn‐
thetic	progesterone‐supplemented	FER	cycles	could	only	be	evalu‐
ated	in	a	larger,	prospectively	gathered	dataset.	Furthermore,	if	such	
a	threshold	is	confirmed	in	a	future	interventional	study,	the	effect	
of	 increased	 progesterone	 supplementation	 could	 be	 evaluated	 in	
FER	cycles	with	low	P4	levels.
The	main	limitation	of	our	study	is	due	to	its	retrospective	nature	
and	 a	 relatively	 limited	 number	 of	 intensively	monitored	 patients,	
even	if	all	consecutive	cases	fulfilling	inclusion	criteria	were	analyzed	
thus	 excluding	 any	 potential	 selection	 bias.	 Also,	 other	 hormonal	
markers	of	pregnancy	viability	such	as	hCG	were	not	evaluated	as	
part	of	an	intensive	hormonal	monitoring;	therefore,	it	was	impossi‐
ble	to	determine	their	prognostic	value	or	compare	them	to	E2	and	
P4	levels.
In	 conclusion,	 our	 retrospective	 study	 has	 shown	 that	 (a)	 en‐
dometrial	 preparation	 protocols	 including	 synthetic	 progestogens	
allow	 the	 precise	 measurement	 of	 an	 endogenous	 progesterone	
rise	 of	 placental	 origin,	 (b)	 different	 patterns	 of	 placental	 E2	 and	
P4	secretion	were	observed	between	the	live	birth	and	miscarriage	
groups,	(c)	the	above	could	predict	the	outcome	of	an	early	first‐tri‐
mester	pregnancy.	Furthermore,	the	use	of	oral	synthetic	progesto‐
gens	 (especially	 dydrogesterone)	 could	 represent	 an	 efficient	 and	
convenient	alternative	 to	 the	more	widely	used	natural	progester‐
one	preparations.
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